Journal of Pharmaceutical and BioTech Industry: A New Open Access Journal

The pharmaceutical and biotechnology industry continues to be one of the most important industry sectors for various reasons. Pharmaceutical manufacturers are essential to the global health and well-being of the public and to the success of many countries’ economies. The total revenue of the worldwide pharmaceutical market was estimated to be USD 1.6 trillion in 2023 [1]. Pharmaceutical companies create millions of jobs across the globe; however, none of these economic measures are more important than the significant impact of this industry sector on people’s health.

The discovery, development, manufacture, and supply of pharmaceutical products, i.e., bench to bed, is one of the most versatile, multi-faceted, and innovative human endeavors. Many science and engineering disciplines contribute to and form the basis of pharmaceutical R&D and manufacturing. Universities, research institutes, state–governmental laboratories, and industry all conduct R&D, while it is the main job of universities to prepare the highly skilled work force required for this endeavor. Regulatory agencies play a major oversight role in ensuring the safety and efficacy of drug products and they support the development of regulatory sciences in emerging areas.

When the COVID-19 pandemic hit, the whole pharmaceutical community comprising pharmaceutical companies, universities, regulatory agencies, and other agencies like the World Health Organization as well as governments/payors, collaborated to ensure the rapid development, manufacture, and supply of the COVID-19 vaccines. The COVID-19 vaccines helped to protect people from severe disease, hospitalization, and death. As a result, millions of lives have been and will be saved thanks to the COVID-19 vaccines. In my opinion, this united effort around COVID-19 vaccines, contributed to by many countries around the world in different ways and capacities, reflects “humanity at its best,” and gives us all hope for the future betterment of health conditions on earth. This concerted effort also once again demonstrated the critical role played by the pharmaceutical and biotechnology industry.

This article announces the launch of an international, peer-reviewed, open access journal—Journal of Pharmaceutical and BioTech Industry (ISSN: 2813-9380) [2]. With the above-mentioned spirit of cooperation among all constituencies of the pharmaceutical community, Journal of Pharmaceutical and BioTech Industry aims to create a platform in which scientists and engineers from academia, industry, regulatory bodies, and other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patients’ well-being. All aspects of the discovery, development, delivery, and manufacturing of drugs (drug substance, drug products including biodrugs, delivery devices, diagnostic agents, etc.) will be covered. The main criteria for publication are originality, high scientific quality, and interest to the pharmaceutical and biotech industry sectors. While studies performed by a single university, laboratory, or company are expected to be the norm, collaborative studies performed by multiple constituencies, e.g., academia–industry, academia–regulator, or academia–industry–regulator are especially welcome, as are inter- or multi-disciplinary studies.

I would like you to consider the Journal of Pharmaceutical and BioTech Industry for publishing your pharmaceutical research and development work, which may well be experimental, theoretical, or both. In fact, to be able to accommodate the diverse publishing needs of our community, especially those in industry and regulatory agencies, we publish short communications, opinions, technical notes, reports, and expert perspectives in addition to the regular research articles and reviews. You will find that our growing Editorial Board has a diversity of scientific expertise from various disciplines pertinent to drug discovery, development, delivery, and manufacturing. I aim to ensure a sufficiently diverse Editorial Board in terms of scientific expertise, gender, race, and geographic location.

The Journal of Pharmaceutical and BioTech Industry offers several benefits to authors. First, the rapid and timely publication of your research results is taken seriously because we all want our exciting findings to be shared with other scientists without any delays. Second, owing to open access, your findings will not be restricted in terms of accessibility. The Creative Commons Attribution (CC BY) license allows you the utmost flexibility to share, copy, redistribute, and adapt your materials. Some print journals impose serious limitations on authors as to how they can share, reuse, and adapt their published materials, which is quite unfavorable to the authors. Third, there is no restriction on the maximum length of the manuscripts or the number of figures and tables. In fact, we recommend that full experimental details and/or methods of study be provided in the submitted research articles.

Finally, I wish to extend a warm welcome to all current and future members of the Editorial Board. As the Founding Editor-in-Chief, I invite experts and leaders from academia, industry, and regulatory agencies to join us. Let us work together to build the Journal of Pharmaceutical and BioTech Industry.